Axial Spondyloarthritis – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis: Ankylosing Spondylitis (US)

Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily involving the sacroiliac joints and the axial skeleton, resulting in chronic back pain and stiffness. The key treatment goals for AS include easing the signs and symptoms of the disease, improving physical function, preventing disability, and slowing or preventing structural damage. TNF-alpha inhibitors (AbbVie’s Humira, Amgen’s Enbrel, Janssen’s Remicade and Simponi / Simponi Aria, UCB’s Cimzia, and infliximab biosimilars) can reduce disease activity in AS and are very effective for patients who require more-potent therapies beyond first-line nonsteroidal anti-inflammatory drugs (NSAIDs). The interleukin (IL)-17 inhibitors—Novartis’s Cosentyx and Eli Lilly’s Taltz—offer an alternative mechanism of action to TNF inhibition. Pfizer’s Xeljanz and AbbVie’s Rinvoq represent the novel JAK inhibitor class—the only nonbiologic targeted therapies for AS.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed AS patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed AS patients?
  • How has Xeljanz been integrated into the treatment algorithm, and what is its source of business?
  • What percentage of AS patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of AS patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

CONTENT HIGHLIGHTS

Markets covered: United States

Key companies: AbbVie, Amgen, Janssen, UCB, Novartis, Eli Lilly

Key drugs: NSAIDs, Humira, Enbrel, Cimzia, Remicade, Simponi, Cosentyx, Taltz, Xeljanz, Rinvoq

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

SOLUTION ENHANCEMENT

The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.

Table of contents

  • Axial Spondyloarthritis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis: Ankylosing Spondylitis (US)
    • Treatment Algorithms CDA Ankylosing Spondylitis US April 2022
    • Treatment Algorithms CDA Ankylosing Spondylitis 2022 Dashboard

Login to access report

launch Related Market Assessment Reports